Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging.

Literature DB >> 9406006

Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging.

O Polat¹, O Gül, I Ozbey, M Ozdikici, Y Bayraktar.

Abstract

In this clinical study, to determine the therapeutic efficacy of interferon (IFN) treatment for Peyronie's disease, we applied interferon alpha-2A (IFN alpha-2A) intralesionally in the treatment of Peyronie plaques in 15 patients and results were evaluated by magnetic resonance imaging (MRI). Patients whose plaque sizes were 0.5 and 1 cm responded better to the treatment. There was about a 90% lessening in the sizes of the plaques of 1.5 cm, 83.3% of 2 cm, as the ones which were 0.5 cm and 1 cm disappeared completely after treatment. As a conclusion, the treatment of Peyronie's disease with IFN alpha-2A is effective and side effects are minimum.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1997 PMID： 9406006 DOI： 10.1007/bf02551115

Source DB: PubMed Journal: Int Urol Nephrol ISSN： 0301-1623 Impact factor: 2.370

11 in total

1. Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro.

Authors: B Berman; M R Duncan
Journal: J Am Acad Dermatol Date: 1989-10 Impact factor: 11.527

2. The treatment of Peyronie's disease with tamoxifen.

Authors: D J Ralph; M D Brooks; G F Bottazzo; J P Pryor
Journal: Br J Urol Date: 1992-12

3. Surgical treatment of Peyronie's disease with a dermal graff.

Authors: C J Devine; C E Horton
Journal: J Urol Date: 1974-01 Impact factor: 7.450

4. Subclinical Peyronie's disease.

Authors: B H Smith
Journal: Am J Clin Pathol Date: 1969-10 Impact factor: 2.493

Review 5. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis.

Authors: K Tanaka; T Yoshioka; C Bieberich; G Jay
Journal: Annu Rev Immunol Date: 1988 Impact factor: 28.527

6. Peyronie's disease.

Authors: J Chesney
Journal: Br J Urol Date: 1975-04

7. Peyronie's disease.

Authors: B H Smith
Journal: Am J Clin Pathol Date: 1966-06 Impact factor: 2.493

8. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma.

Authors: M R Duncan; B Berman; U O Nseyo
Journal: Scand J Urol Nephrol Date: 1991

9. Interferon-alpha and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture.

Authors: V M Kähäri; J Heino; T Vuorio; E Vuorio
Journal: Biochim Biophys Acta Date: 1988-01-18

10. Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons.

Authors: M R Duncan; B Berman
Journal: J Clin Invest Date: 1987-05 Impact factor: 14.808

5 in total

Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging.

1. Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro.

2. The treatment of Peyronie's disease with tamoxifen.

3. Surgical treatment of Peyronie's disease with a dermal graff.

4. Subclinical Peyronie's disease.

Review 5. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis.

6. Peyronie's disease.

7. Peyronie's disease.

8. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma.

9. Interferon-alpha and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture.

10. Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons.

1. PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.

Review 2. Treatment of Peyronie's disease: 2012 update.

Review 3. Pharmacological Management of Peyronie's Disease.

4. Current and emerging treatment options for Peyronie's disease.

Review 5. Peyronie's disease: What's around the bend?